UPPSALA, Sweden, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced a new publication on Olink’s PEA technology, providing an invaluable resource to the scientific community.
We are proud to share a recently published peer-review publication in Molecular and Cellular Proteomics. This is the first publication describing the details behind Olink’s Explore platform, with Proximity Extension Assay (PEA) technology coupled to readout using NGS (Next Generation Sequencing). Olink’s Target panels with PEA coupled to qPCR readout have been cited previously in over 700 peer-publications.
The article describes the technology, workflow and protocol for the ground-breaking method based on the already proven PEA technology in combination with NGS read-out. For many years, there has been a clear need and a growing demand for larger proteomic studies that can exploit the diagnostic potential held within the low abundant plasma proteome. Olink® Explore 1536 was launched in June 2020 and with the launch of Olink® Explore 3072, almost 3000 validated proteins can now be measured simultaneously and analysed with 384 samples per run.
The protocol described in the new publication contains an innovative and automated sample preparation workflow for high throughput readout while consuming a minimal amount of sample. The performance of the platform has already been demonstrated in various disease and wellness studies detecting novel biomarkers for early diagnosis and disease monitoring, as well as providing a better understanding of the proteome in healthy as well as disease cohorts. Despite the relatively recent launch of the Explore platform, this has already led to several publications in prestigious peer-reviewed publications. The enthusiastic uptake of this game-changing technology by the scientific community will likely result in a rapidly increasing number of publications citing its use, and the new publication written by members of Olink’s outstanding R&D team will be an important resource and reference point for future publications from our customers. The original publication describing PEA with qPCR readout from 2014 has been cited well over 350 times to date.
Proteins are described as the building blocks of life and are required for the structure and function of all cells in the body. They are the main targets in drug development and in diagnostic testing and are commonly monitored over time as they represent the interaction between phenotype and environmental and lifestyle factors. Proteins can be used as strong predictors for diseases as well as for patient stratification and disease subtyping and may also act as surrogate markers in clinical trials to predict clinically meaningful endpoints. However, proteins are far more complex to measure than DNA, and most current proteomics technologies have failed to deliver on critical performance parameters such as specificity, sensitivity, throughput, and dynamic range. The targeted approach of immunoassays has multiple advantages over untargeted approaches such as mass spectrometry, the most important of these being assay sensitivity, throughput and reproducibility following sample preparation.
“We are very proud to further develop our already commercialized technology with disruptive methods and use the already proven PEA technology in combination with NGS read-out which has led to an increased throughput (128x compared with Olink® Target 96). This advancement will have a major impact on the discovery of new biomarkers for disease prediction and prognosis and contribute to the development of the rapidly evolving fields of wellness monitoring and precision medicine,” says Ida Grundberg, Chief Scientific Officer, of Olink Proteomics, one of the authors of the abstract.
Read the publication here
Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.
This release may contain forward-looking statements within the meaning of applicable securities laws, including the U.S. Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Olink’s strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs as of the date hereof and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to Olink’s business, operations, supply chain, strategy, goals and anticipated timelines, including for the delivery of Olink Explore 3072 and the expansion of the Explore platform, competition, and other risks identified in the section entitled “Risk Factors” in Olink’s Registration Statement on Form F-1, as amended (File No. 333-253818) filed with the U.S. Securities and Exchange Commission (SEC) and in the other filings, reports, and documents Olink files with the SEC from time to time. Olink expressly disclaims any obligation to update any forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.
For more information please contact:
Jan Medina, CFA
VP Investor Relations & Capital Markets, Olink
Mobile: +1 617 802 4157
Corporate Communications Manager, Olink
Mobile: + 46 768 775 275